NCT02733796 is a clinical trial in Zika Virus, sponsored by Institute of Tropical Medicine, Belgium.

Who is sponsoring NCT02733796?

NCT02733796 is sponsored by Institute of Tropical Medicine, Belgium.

What condition does NCT02733796 study?

NCT02733796 studies Zika Virus, Zika Virus Disease, Virus Shedding, Transmission.

Is NCT02733796 still recruiting?

NCT02733796 is currently completed. Last updated 2 March 2021.

Last reviewed 2021-03-02 · How we verify

NCT02733796

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Persistence of Zika Virus in Semen After Acute Infection

Completed Last updated 2 March 2021

What this trial tests

trial in Zika Virus in 15 participants. Completed in 1 September 2017.

Timeline

1 February 2016

Primary endpoint
1 May 2017

1 September 2017

Quick facts

Lead sponsor	Institute of Tropical Medicine, Belgium
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	1 February 2016
Primary completion	1 May 2017
Estimated completion	1 September 2017
Sites	1 location across Belgium

Conditions studied

Zika Virus — all drugs for Zika Virus →
Zika Virus Disease — all drugs for Zika Virus Disease →
Virus Shedding — all drugs for Virus Shedding →
Transmission — all drugs for Transmission →

Sponsor

Institute of Tropical Medicine, Belgium

Who can join

Adults 18 to 80, male only, with Zika Virus or Zika Virus Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective observational laboratory evaluation of the persistence rate of zika virus (ZIKV) infection in semen by real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), and assessment of ZIKV replication-competence in semen by isolation of ZIKV. Evaluation of the persistence of ZIKV and its replication-competence in semen samples will increase the understanding of the risk of sexual transmission of ZIKV infection in the post-viremic phase in non-epidemic settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Institute of Tropical Medicine, Belgium trials

Trials by the same sponsor.

NCT07463040 — Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) · Phase 3 · not yet recruiting
NCT07174648 — Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. · not yet recruiting
NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
NCT07342829 — Prospective Follow-up After MVA-BN Booster Vaccination · not yet recruiting
NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02733796 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Tropical Medicine, Belgium
Last refreshed: 2 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02733796.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing